A RANDOMIZED, SINGLE-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE, PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS (PK), AND PHARMACODYNAMICS (PD) OF TAK-272 IN HEALTHY ADULT NON-ELDERLY AND ELDERLY MALE SUBJECTS

被引：0
|
作者：
Matsuno, K. [2 ]
Tanaka, S. [2 ]
Hashimoto, T. [1 ]
Nakamichi, H. [4 ]
Komura, E. [3 ]
机构：
[1] Takeda Pharmaceut Co Ltd, Biostat, Osaka, Japan
[2] Takeda Pharmaceut Co Ltd, Clin Pharmacol, Osaka, Japan
[3] Takeda Pharmaceut Co Ltd, Clin Sci, Osaka, Japan
[4] Takeda Pharmaceut Co Ltd, Pharmacovigilance, Osaka, Japan
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2017年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
SP428
引用
收藏
页码：265 / +
页数：2
相关论文
共 50 条
  • [21] Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine
    de Hoon, Jan
    Van Hecken, Anne
    Vandermeulen, Corinne
    Yan, Lucy
    Smith, Brian
    Chen, Jiyun Sunny
    Bautista, Edgar
    Hamilton, Lisa
    Waksman, Javier
    Thuy Vu
    Vargas, Gabriel
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (05) : 815 - 825
  • [22] Safety and immunogenicity of pentavalent rotavirus vaccine in a randomized, double-blind, placebo-controlled study in healthy elderly subjects
    Lawrence, Jody
    He, Su
    Martin, Jason
    Schoedel, Florian
    Ciarlet, Max
    Murray, Alexander V.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (08) : 2247 - 2254
  • [23] A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Intravenous and Subcutaneous Garadacimab (CSL312) in Healthy Subjects
    McKenzie, Andrew
    Roberts, Anthony
    Malandkar, Sourabh
    Feuersenger, Henrike
    Panousis, Con
    Pawaskar, Dipti
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB137 - AB137
  • [24] A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of AMG145
    Dias, Clapton
    Shaywitz, Adam
    Smith, Brian
    Emery, Maurice
    Bing, Gao
    Gibbs, John
    Wishner, Bill
    Stolman, Dina
    Crispino, Caroline
    Crispino, Caroline
    Cook, Blaire
    Colbert, Alex
    Retter, Marc
    Xu, Ren
    Matson, Mark
    CIRCULATION, 2011, 124 (21)
  • [25] A phase 1, single-center, placebo-controlled, double-blind study to assess the single dose pharmacokinetics of CC-8490 in healthy volunteers
    Scheffler, M
    Wu, A
    Teo, S
    Friedman, G
    Faleck, H
    Zeldis, J
    Stirling, DI
    Thomas, SD
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (09): : 1030 - 1030
  • [26] Randomized, double-blind, placebo-controlled phase 1 study to evaluate the safety and pharmacokinetics of high doses of ubiquinol in healthy adults
    Mitsui, Jun
    Matsukawa, Takashi
    Tanaka, Masaki
    Saito-Sato, Naoko
    Nakamoto, Fumiko Kusunoki
    Yasuda, Tsutomu
    Naruse, Hiroya
    Matsukawa, Miho Kawabe
    Ishiura, Hiroyuki
    Nagase, Midori
    Yamamoto, Yorihiro
    Kuzuyama, Haruko
    Wada, Ikue
    Ga, Toshio
    Yamazaki, Tsutomu
    Moritoyo, Takashi
    Tsuji, Shoji
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2022, 10 (01): : 14 - 24
  • [27] A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects
    Xie, Panpan
    Abildlund, Morten T.
    Baekdal, Tine A.
    He, Xuemei
    Lyauk, Yassine K.
    Patted, Usha Rani H.
    Ning, Zu
    Shi, Aixin
    DIABETES OBESITY & METABOLISM, 2024, 26 (08): : 3068 - 3077
  • [28] Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects-A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study
    He, Kun
    Wei, Fang
    Chen, Hong
    Zhang, Yanyan
    Sheng, Zhen
    Wen, Qing
    DIABETES, 2023, 72
  • [29] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PH1 STUDY TO EVALUATE SAFETY AND PHARMACOKINETICS OF AMG203 (NAMILUMAB) IN HEALTHY ADULT JAPANESE/CAUCASIAN MALE SUBJECTS
    Tanaka, S.
    Harada, S.
    Hiramatsu, N.
    Nakaya, R.
    Kawamura, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S89 - S89
  • [30] A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, ASCENDING SINGLE-DOSE, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF AMG 529, A NOVEL ANTI-ASGR1 MONOCLONAL ANTIBODY, IN HEALTHY SUBJECTS
    Janiszewski, Mariano
    Sohn, Winnie
    Su, Cheng
    Hsu, Yi Hsiang
    Finger, Elizabeth
    Kaufman, Allegra
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1755 - 1755
12345